Kornimate/medical-research-clean huggingface dataset:
additional effects of surface electromyographic biofeedback on post facilitation stretching and strengthening in lower crossed syndrome;a randomized control trial

Conditions: Lower Cross Syndrome

Summary: this study is a randomised control trial and the purpose of this study is to determine the additional effects of surface electromyographic biofeedback on post facilitation stretching and strengthening in lower crossed syndrome. .

participants will be recruited into their respective groups using a coin toss method. lower crossed syndrome will be assessed using the following tests: prone hip extension test trunk flexion strength test tightness in erector spinae modified thomas test

Eligibility criteria:
inclusion criteria: * age 19-35 years * both genders * positive modified thomas test * positive prone hip extension strength test * positive trunk flexion strength test * tight erector spinae * bmi normal (18.5-24.9 kg/m2) * local intermittent lumbar pain * moderate pain (nprs 3-7) * painless movement and activity * pain only produced by sustained loading in relevant position, which is then relieved on moving from that pos exclusion criteria: * acute flare of lbp * centralization and peripheralization of pain * signs of stenosis(leg symptoms when walking that are eased upon flexion) * pain due to repetitive movements * paresthesia/numbness * structual deformity(kyphosis, spondylosis, spondylolisthesis,scoliosis and joint contractures) * curve reversal * pregnancy * post surgery * degenerative and inflammatory spine diseases
cannabidiol usage as an adjunct therapy for crohn's disease

Conditions: Crohn Disease; Inflammatory Bowel Diseases; Cannabis

Summary: to date, few studies have assessed the efficacy and safety of cannabinoids, compounds derived from the cannabis plant, in patients with crohn's disease. our study seeks to pilot a randomized, placebo-controlled trial assessing the efficacy and safety of oral cannabinoids as an adjunct therapy in patients with crohn's disease.

crohn's disease is a type of inflammatory disease which can affect any portion of the gastrointestinal tract, from the mouth to the perianal area. symptoms depend on location of the disease, however, many patients experience some aspect of recurrent abdominal pain, nausea, emesis, and unintentional weight loss. a common and challenging dilemma is how to manage patients who continue to have some degree of symptoms despite a common treatment regimen typically consisting of corticosteroids, thiopurines, methotrexate, or anti-tnf alpha therapies. with the recent wave of medicinal cannabis legalization in many states, many patients have begun using cannabis or commercially available cannabidiol-containing compounds as an adjunct therapy for their symptoms related to chronic inflammation and pain.

Eligibility criteria:
inclusion criteria: * age 18 or older * english-speaking * ileal and/or ileocolonic involvement as demonstrated by most recent endoscopy * short cdai score \>150 * have not received oral or intravenous steroids for \>1 month, or with stable dose for \>1 month if currently taking * stable dose of aza for \>1 month, if currently taking * stable dose of anti-tnf inhibitor for \>1 month, if currently taking exclusion criteria: * pregnant or intend to become pregnant in the next 6 months * major abdominal surgery within the past 3 months
aripiprazole for the treatment of patients with agitation associated with dementia of the alzheimer's type

Conditions: Agitation Associated With Dementia of the Alzheimer's Type

Summary: to evaluate the efficacy (based on mean change in cohen-mansfield agitation inventory \[cmai\] total score from baseline as the primary efficacy variable), dose-response, and safety of aripiprazole at 2, 3, and 6 mg/day in comparison with placebo in patients with agitation associated with alzheimer's type dementia

this trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, comparison trial to assess the efficacy and safety of aripiprazole in patients with agitation associated with alzheimer's type dementia. screening period is 4 weeks. patients are randomly assigned to one of 4 groups, and treatment period is 10 weeks. period of post-treatment observation is 30 days.

Eligibility criteria:
inclusion criteria: * patients whose legal representatives can provide informed consent (informed consent from the patients where possible). * patients who satisfy both of the following diagnostic criteria: * diagnosis of major neurocognitive disorder due to alzheimer's disease according to diagnostic and statistical manual of mental disorders (dsm-5) * diagnosis of probable alzheimer's disease according to national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorders association (nincds-adrda) * hospitalized patients or care facility patients * patients with an mini-mental state examination (mmse) score of 1 to 22 exclusion criteria: * patients with complications of dementia or memory impairment other than alzheimer's type dementia * dementia patients with a modified hachinski ischemic score of 5 or higher * patients with psychological symptoms or behavioral disorders that are clearly due to other medical conditions or substances * patients with a complication or history of stroke or transient ischemic attack, except for asymptomatic stroke * patients with heart failure classified as new york heart asscoiation (nyha） iii or iv * patients who require drug therapy for arrhythmia or ischemic heart disease * body weight of less than 30 kg * patients with a high risk of suicide * patients with a complication or history of seizure disorder * patients with a complication or history of neuroleptic malignant syndrome, tardive dyskinesia, paralytic ileus, or rhabdomyolysis * patients with thyroid disease (except if the disease has been stabilized with drug therapy for 3 months or longer prior to time of informed consent)

Keywords: alzeheimer
exercise hemodynamics in patients with pulmonary fibrosis

Conditions: Exercise Pulmonary Hypertension

Summary: the study evaluates the rest and exercise hemodynamics of patients presenting either idiopathic fibrotic pulmonary disease or pulmonary fibrosis secondary to connective tissue disease.

patients with fibrotic pulmonary disease of the above origin will undergo detailed assessment of functional status with the following examinations: pulmonary function tests, echocardiogram, 6 minute exercise test, cardiopulmonary exercise test (in the absence of contra-indications) and finally right heart catheterization. hemodynamic assessment will take place at rest and at exercise following the exercise protocol that was recommended by herve et al (erj 2015) using a cycle ergometer at bedside. the purposes of the study are: 1. to evaluate the response of the hemodynamic parameters at exercise compared to the resting parameters in this patient group. 2. to discriminate between precapillary from postcapillary etiology of pulmonary hypertension. 3. to correlate non-invasive parameters of functional limitation with invasive hemodynamic parameters. 4. to assess the prognostic role of exercise induced pulmonary hypertension in the specific patient group.

Eligibility criteria:
inclusion criteria: 1. diagnosis of pulmonary fibrosis secondary to connective tissue disease, according to the american college of rheumatology/european league against rheumatism (acr-eular) revised classification criteria , or diagnosis of idiopathic fibrotic diffuse pulmonary disease according to american thoracic society/european respiratory society (ats/ers) guidelines 2. forced vital capacity (fvc) ≥ 40 % exclusion criteria: 1. presence of contra-indications to exercise tests, such as acute myocardial infarction, unstable angina, uncontrollable arrythmia or skeletal disease that limits the ability to exercise. 2. history of pulmonary embolism during the year before enrollment 3. presence of severe valvular disease. 4. current treatment with vasoactive drugs of the pulmonary circulation 5. pulmonary wedge pressure (pawp) at rest \> 15 mmhg
sintilimab combined with docetaxel for standard chemotherapy failure non-driver gene mutation metastatic non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to assess the safety and effectiveness of sintilimab combined with docetaxel in non-driver gene mutation nsclc patients who failed with double platinum-based chemotherapy


Eligibility criteria:
inclusion criteria: * life expectancy exceeds 3 months * the investigator confirmed at least one measurable lesion according to the recist 1.1 standard. exclusion criteria: * small cell lung cancer or small cell lung cancer * currently involved in interventional clinical research or treatment, or have received other research drugs or used research equipment within 4 weeks prior to the first dose; * previously received the following treatments: anti-pd-1, anti-pd-l1 or anti-pd-l2 drugs or drugs that stimulate or synergistically inhibit t cell receptors (eg, ctla-4, ox-40, cd137);
respiratory quotient and food liking, food wanting and food consumption

Conditions: Obesity

Summary: the purpose of this study is to observe the influence of carbohydrate-to-fat balance on liking, wanting and food consumption in humans. 16 normal-weight men (age: 23 ± 3 y)had completed a randomized 4-condition crossover study. the sessions differed by the composition of the breakfast which was rich in carbohydrates (hcb), low in carbohydrates (lcb), rich in fat (hfb) and low in fat (lfb). the hcb and hfb contained 2072 kj, while the lcb and lfb contained 565 kj. two hours and 20 min later, energy expenditure (ee) and respiratory quotient (rq) were measured before olfactory liking for 4 foods items and then ad libitum energy intake (ei) during a snack (sweet and fatty toast) were evaluated.

in accordance with the carbohydrate-based models of feeding, one may expect that food choices as well as "liking" and "wanting" (the two components of the reward system) could be influenced by glycogen stores and the carbohydrate-to-fat balance. more precisely, one may expect that a high fat oxidation rate could increase liking and wanting carbohydrates to replenish glycogen stores and conversely, that a high carbohydrate oxidation rate could produce the reverse. in order to validate this hypothesis, the present study has been conducted to investigate in humans the influence of the carbohydrate-to-fat oxidation ratio on carbohydrate-to-fat selection and the food reward system.

Eligibility criteria:
inclusion criteria: * good health * absence of medication * moderate physical activity (irregular and less than 5 h/wk) * low-smoking habit (less than 5 cigarettes/d) * normal body mass index (20\< bmi \<25) exclusion criteria: * eating disorders * dieting or fasting * aversions for the foods offered and elevated 'cognitive restriction of eating' (score ≥ 7) according to the three factor eating questionnaire

Keywords: energy intake energy expenditure macronutrient selection
the effectiveness of information and relaxation on pre-procedural block anxiety and procedural discomfort during medial branch block

Conditions: Chronic Pain

Summary: patient presenting to chronic pain clinics frequently undergo diagnostic and therapeutic spinal injections as part of their treatment. these procedures can cause significant level of apprehension in patients, which can lead to increased procedural times, increased procedural pain and reluctance to continue with the treatment program. it appears that certain interventions could reduce the anxiety and catastrophization levels and modify pain perception during medical procedures. the investigators therefore sought to evaluate the effect of a single 30 minutes information session which includes relaxation training administered 5 to 6 days before the nerve block procedure on patient's anxiety and catastrophization levels prior to the procedure and pain scores during the procedure, as well as the overall level of satisfaction with care received.


Eligibility criteria:
inclusion criteria: * patient scheduled to have a medial branch block * over 18 years of age exclusion criteria: * adult able to give their own consent * patients who had a previous nerve block * patients who have a major psychiatric illness * patients who do not understand english or french

Keywords: chronic pain anxiety intervention information relaxation
a study to evaluate the efficacy, safety, and pharmacokinetics of mtps9579a in patients with asthma requiring inhaled corticosteroids and a second controller

Conditions: Asthma

Summary: this is a phase iia, randomized, placebo-controlled, double-blind, multicenter, two-arm study to evaluate the efficacy, safety, and pharmacokinetics of mtps9579a as an add-on therapy in patients with uncontrolled moderate to severe asthma who are receiving daily ics therapy and at least one of the following additional controller medications: long-acting beta-agonist (laba), leukotriene modulator (leukotriene modifier \[ltm\] or leukotriene receptor antagonist \[ltra\]), long-acting muscarinic antagonist (lama), or long-acting theophylline preparation.


Eligibility criteria:
inclusion criteria: * documented physician-diagnosed asthma for at least 12 months prior to screening * treatment with asthma controller therapy (daily ics \[fluticasone propionate or equivalent\] and at least one additional controller therapy \[laba, lama, ltm/ltra\]) for \>= 3 months prior to screening, with no changes within 4 weeks prior to screening or during the screening period and no anticipated changes in controller dosing regimens throughout the study * documented history of \>= 2 asthma exacerbation within the 12 months prior to screening while on daily ics maintenance therapy * for women of childbearing potential: agreement to remain abstinent or use contraception for men: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm exclusion criteria: * history or evidence of vocal cord dysfunction, reactive airways dysfunction syndrome, hyperventilation associated with panic attacks, or other mimics of asthma * history or evidence of significant respiratory disease other than asthma, including occupational asthma, aspirin-sensitive asthma, asthma-chronic obstructive pulmonary disease (copd) overlap syndrome, bronchiolitis, interstitial lung disease, or copd * current smoker, electronic cigarette (e-cigarette) user, former smoker with smoking history of \> 10 pack-years, former e-cigarette user with an e-cigarette history of at least daily use for \>=10 years, or unwilling to abstain from smoking and/or e-cigarette use from the time of consent through the completion of the study * history or evidence of any clinically significant medical condition/disease or abnormalities in laboratory tests that, in the investigator's judgment, precludes the patient's safe participation and completion of the study, or interferes with the conduct and interpretation of the study * active malignancy or history of malignancy within 5 years of screening, except for appropriately treated non-melanoma skin carcinoma, cervical carcinoma in situ, breast ductal carcinoma in situ, or stage i uterine cancer * pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the final dose of mtps9579a * positive for tb at screening
preoperative systemic therapy for colorectal cancer peritoneal metastases

Conditions: Colorectal Neoplasms; Colorectal Cancer; Colorectal Cancer Metastatic; Peritoneal Metastases; Peritoneal Cancer; Peritoneal Neoplasms; Chemotherapy Effect; Cytoreductive Surgery; Hyperthermic Intraperitoneal Chemotherapy

Summary: this is an open-label, parallel-group, phase 2 randomized trial which randomizes patients with isolated resectable colorectal cancer peritoneal metastases to receive preoperative systematic therapy followed by crs+hipec and postoperative chemotherapy or upfront crs+hipec followed by postoperative chemotherapy.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 or 1; * historically and radiologically confirmed colorectal cancer peritoneal metastasis except for appendical origin; * tolerable to scheduled chemotherapy; * no evidence of extraperitoneal metastases at enrollment; * resectable disease determined by radiological and laparoscopy/laparotomy; * no systematic therapy within 6 months before enrollment; * tolerable to cytoreductive surgery. exclusion criteria: * without adequate organ function (e.g. :neutrophil countt≤1.5×10\^9/l, or platelets≤75×10\^12/l，or hemoglobin\<90g/l, or aminotransferase、aspartate aminotransferaseast\<2.5uln, or total bilirubin\<1.5uln, or creatinine\<1.5uln; * emergency surgery; * recent thromboembolic event or cerebrovascular disease (12 months before enrollment); * pregnancy or lactation * comorbid with severe physical or mental disease.
predictive role of glucose/potassium ratio on mortality in major burns.

Conditions: Burns; Burn Injury; Inhalation Injury

Summary: the aim of this observational study is to investigate the role of the glucose-potassium ratio in predicting mortality in patients with major burn trauma. the main question it aims to answer is: can the glucose-potassium ratio predict mortality in major burn patients? the glucose-to-potassium ratios of major burn patients at the time of initial hospitalization will be determined, and their relationship with mortality will be analyzed.

major burns, especially electrical burns, facial burns, inhalation burns, burns with large burn surface areas, and deep burns, have a high mortality risk. early detection of this risk may be critical to reducing mortality rates. for this reason, trauma centers are working on rapid and effective prognostic markers. in trauma and stress situations, glucose levels rise while potassium levels fall due to increased catecholamines. the literature reports that hyperglycemia, also known as the glucose-potassium ratio, can rapidly and effectively predict morbidity and mortality in patients suffering from subarachnoid hemorrhage, pulmonary embolism, traumatic brain injury, or blunt abdominal trauma. many publications show that increased glucose is associated with mortality and morbidity in critical illnesses and trauma. the isolated glucose-potassium ratio has a higher predictive ability for mortality and morbidity compared to glucose and potassium levels. in this study, investigators aimed to examine the prognostic value of the glucose-to-potassium ratio in participants with major burn trauma.

Eligibility criteria:
inclusion criteria: * all burns \>40% of total body surface area (2nd degree or deeper) * burns with inhalation injury * burns \>20% of total body surface area 3nd degree or deeper exclusion criteria: * first degree burns * patients have more than 24 hours since the onset of burn trauma * patients with diabetes mellitus * patients with chronic renal failure * patients taking potassium-modifying medication * patients with missing data
intensive goal training for adolescents with cerebral palsy

Conditions: Cerebral Palsy

Summary: adolescents with cerebral palsy (cp) present important limitations for the performance of daily living activities. the aims of the study is to evaluate the feasibility and effects of an intensive goal training protocol for adolescents with cp. he hypothesize that adolescents submitted to the studied protocol will present improvements in performance and satisfaction of prioritized functional goals.

we will conduct a feasibility study to assess the implementation and the possible effects of an intensive individualized goal training with adolescents with cp. adolescents will select up to 5 functional goals to be trained during a 2 weeks, 3 hour-daily training, totalling 30 hours across 2 weeks. moreover, they will be asked to daily practice these activities at home along the intervention period.

Eligibility criteria:
inclusion criteria: * medical diagnosis of bilateral cp; * age between 12 and 17 years old; * manual ability classification system (macs) ranging from levels i to iii; * gross motor function classification system (gmfcs) ranging from levels i to iv; * ability to understand verbal instructions. exclusion criteria: * botulinum toxin or surgery in upper limbs in the previous 6 months of the study.
inflammatory consequences of crystalloids in severely burned patients

Conditions: Burns

Summary: this is a pilot study, but the investigators will also observe key immunological events with potential significance. the global objective is to study the inflammatory profiles of plasmalyte and ringer's lactate used in the initial massive fluid resuscitation of severely burned patients. on the long term, the investigators will identify the crystalloid that prevents hyperactivation of macrophages and death of severely burned patients.

the investigators have 4 specific objectives. first, the investigators will compare the activation profiles of macrophages and neutrophils in patients admitted to the severely burned unit with regards to the crystalloids used. secondly, the investigators will assess the differences in the sofa scores according to the crystalloids used. thirdly, the investigators will evaluate the impact of crystalloids in the quality of skin grafts performed on severely burned patients. lastly, with the help of a patient partner, the investigators will determine the right immunological terminology of the study for a non-scientific population.

Eligibility criteria:
inclusion criteria: * admission to the chum * more than 20% of burned area * first blood withdrawal in the first 24 hours following burn exclusion criteria: * immunosuppression * chemotherapy 6 months before admission * radiotherapy 6 months before admission * autoimmune diseases * neoplasia * pregnancy * severe infections * cardiac dysfunctions * renal dysfunction * hepatic dysfunctions * hepatitis c * hiv

Keywords: resuscitation crystalloids inflammation